Copper IUD Physiology: Menorrhagia, Iron Kinetics, and the Copper-Zinc Axis

[Image: Endometrial cross-section showing prostaglandin, fibrinolysis, and microvascular changes near a copper IUD]

Cu-IUD-associated increased menstrual blood loss is driven by the local inflammatory response rather than any systemic hormonal effect. Cupric ions and the foreign-body reaction increase endometrial production of vasodilatory prostaglandins (notably PGE2 and prostacyclin/PGI2), shifting the local prostaglandin balance toward vasodilation and impaired platelet aggregation. Concurrently, endometrial fibrinolytic activity is elevated — increased plasminogen activator activity enhances clot breakdown, reducing the hemostatic plugging that normally limits menstrual loss.

There is also increased endometrial microvascular density and fragility in the vicinity of the device, and elevated expression of vascular endothelial growth factor. The net effect is heavier and often longer menses, frequently with increased dysmenorrhea from the prostaglandin elevation. This is the mechanistic basis for the observation that NSAIDs (prostaglandin synthase inhibitors) reduce both Cu-IUD bleeding and cramping — and why magnesium, with its smooth-muscle and prostaglandin-modulating effects, is a rational adjunct for the cramping component.

[Image: Graph of ferritin declining ahead of hemoglobin across successive menstrual cycles]

The hematologic consequence is best understood as a recurring monthly negative iron balance rather than an acute event. Each milliliter of blood contains approximately 0.5 mg of iron; a 50–75% increase in menstrual loss superimposed on baseline menstruation can shift a woman from iron-neutral to a sustained monthly deficit of several milligrams — frequently exceeding what dietary absorption (typically 1–2 mg/day net) can compensate.

The sequence of depletion is diagnostically important. Storage iron (ferritin) is mobilized first; serum ferritin therefore declines well before hemoglobin, making ferritin — not hemoglobin or a standard CBC — the sensitive early marker. Iron-deficiency-without-anemia (ferritin <30 ng/mL with normal hemoglobin) is symptomatic in its own right: fatigue, impaired cognition, hair shedding (telogen effluvium), cold intolerance, restless legs, and pica. Because ferritin is also an acute-phase reactant, the Cu-IUD's low-grade endometrial inflammation can modestly elevate it, occasionally masking true depletion — a soluble transferrin receptor or reticulocyte hemoglobin measurement resolves ambiguous cases.

[Image: Diagram of enterocyte iron absorption with vitamin C enhancement and polyphenol inhibition]

Repletion strategy must match a recurring loss, favoring tolerable daily forms over high-dose regimens that impair adherence through GI effects. Ferrous bisglycinate (a chelated amino-acid iron) is absorbed at roughly 4× the fractional rate of ferrous sulfate with substantially fewer GI adverse effects (Bovell-Benjamin et al., Am J Clin Nutr, 2000), making it well-suited to the long-term repletion a Cu-IUD requires.

Absorption optimization is non-trivial because non-heme iron uptake is heavily modifiable. Ascorbic acid reduces ferric to absorbable ferrous iron and chelates it through the enterocyte, enhancing fractional absorption several-fold — hence co-administration with vitamin C. Conversely, polyphenols (tea, coffee), calcium, and phytates substantially inhibit absorption, so iron is separated from these. Emerging evidence on alternate-day dosing (mitigating hepcidin-mediated absorption blockade that follows a daily dose) is relevant for optimizing efficiency, though consistent daily intake paired with vitamin C remains the pragmatic baseline for an ongoing monthly deficit.

[Image: Copper-zinc competitive absorption diagram alongside a preserved four-phase cycle]

Cu-IUD use is associated with elevated serum and intrauterine copper (Imani et al., J Trace Elem Med Biol, 2014). Copper and zinc are competitive antagonists at the level of intestinal absorption — both partly share the DMT1 transporter and induce metallothionein, which preferentially sequesters copper — and in systemic distribution. Sustained copper elevation can therefore depress zinc status over time, with downstream effects on immune function, epithelial integrity, and the numerous zinc-dependent metalloenzymes.

The corrective is a moderate zinc dose (15–25 mg bisglycinate) calibrated to restore the copper:zinc ratio rather than to override it; supraphysiologic zinc (>40 mg chronically) would itself induce copper deficiency and is avoided. No copper supplementation is indicated — the device is the copper source. Crucially, because the Cu-IUD preserves ovulatory cyclicity, the repletion layer is superimposed on a phase-based foundation, not a steady-state one: the menstrual phase emphasizes iron and anti-prostaglandin support coinciding with peak loss, while follicular and luteal support proceed normally. This is the inverse of the hormonal-contraception model, where cycle suppression mandates a fixed daily stack.